Treatment of Type 1 Diabetes Mellitus by Increasing Human Leukocyte Antigen-G Expression with Polymeric Nanoparticles Using Gene Therapy

Iranian Journal of Medical Hypotheses & Ideas 12/2009; 3.

ABSTRACT Type 1 Diabetes Mellitus in most cases is an autoimmune disease. Insulin injection is just a symptom therapy that is bothering for the patient and usually does not correct the blood glucose level appropriately. Attempts to replace the lost pancreatic cells such as islet and stem cell transplantation were not permanent cures because the original problem which was autoimmunity still existed. On the other hand, while using allogenic cells, immune system rejects the foreign cells. We suppose an approach to use the cells that are not affected by autoimmunity and can divide and replace the pancreatic β cells. Human Leukocyte Antigen-G (HLA-G) protein suppresses the im-mune system by affecting the T cells and natural killer cells and some other immune system cells and is responsible for keeping the fetus from maternal immune system in pregnancy. Autologous mesenchymal stem cells and insulin producing cells are candi-date cells to be transfected with HLA-G gene. Transplantation of these genetically modified autologous stem cells to the patient leads to permanent production of β cells that are out of the reach of the immune system. As they are autologous cells, there is no fear of rejection. Nanoparticle based gene delivery is the desired procedure since there is no fear of tumor genesis with this method.

Download full-text


Available from: Mohsen Khosravi, Aug 24, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human leukocyte antigen (HLA)-G retains the capacity to modulate immune responses, favoring the establishment of tolerance in solid-tissue allotransplants. To better understand the mechanisms that promote corneal allograft survival, we investigated whether HLA-G was an immunoregulatory factor involved in corneal immunology. We therefore sought HLA-G expression in corneal tissues. Corneal transplantation consists in replacing the center of a diseased cornea with normal corneal tissue. Two corneal parts are not used in such surgery: diseased central corneal tissue and peripheral normal cornea. For this study, we used healthy corneas obtained from deceased donors and diseased corneas obtained from patients with pseudophakic bullous keratopathy or keratoconus who had undergone corneal transplantation. Immunohistochemical analysis carried out on the cryopreserved corneas showed a positive immunohistochemical staining with anti-HLA-G, anti-HLA-A, -B, and -C, and anti-HLA class I monoclonal antibodies. Staining was obtained for keratocytes, epithelial cells, and endothelial cells from both healthy and pathologic human corneas, revealing the presence of HLA class I proteins, including HLA-G. HLA-G transcripts were detected in normal cornea by reverse transcriptase-polymerase chain reaction with a classical pattern of alternative splicing. The detection of HLA-G protein in adult corneas leads to the conclusion that this protein may contribute to the maintenance of the privileged immune status of cornea.
    Human Immunology 12/2003; 64(11):1039-44. DOI:10.1016/j.humimm.2003.08.346 · 2.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Blood can provide a valuable source for the generation of stem cells. Herein we identified a novel cell population from adult human blood, designated peripheral blood insulin-producing cells (PB-IPC). Phenotypic analysis demonstrated that PB-IPC displayed the embryonic stem (ES) cell-associated transcription factors including Oct-4 and Nanog, along with the hematopoietic markers CD9, CD45, and CD117; but lacked expression of the hematopoietic stem cell marker CD34 as well as lymphocyte and monocyte/macrophage markers. Notably, in vitro and in vivo characterization revealed that PB-IPC demonstrated characteristics of islet beta cell progenitors including the expression of beta cell-specific insulin gene transcription factors and prohormone convertases, production of insulin, formation of insulin granules, and the ability to reduce hyperglycemia and migrate into pancreatic islets after transplantation into the diabetic mice. These findings may open up new avenues for autologous blood stem cell-based therapies for diabetes.
    Biochemical and Biophysical Research Communications 09/2007; 360(1):205-11. DOI:10.1016/j.bbrc.2007.06.035 · 2.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 1 diabetes mellitus (T1DM) is characterized by an impairment of the insulin-secreting beta cells with an immunologic base. Inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, and free radicals are believed to play key roles in destruction of pancreatic β cells. The present study was designed to investigate the effect of Silybum marianum seed extract (silymarin), a combination of several flavonolignans with immunomodulatory, anti-oxidant, and anti-inflammatory potential on streptozotocin (STZ)-induced T1DM in mouse. Experimental T1DM was induced in male albino mice by IV injection of multiplelow- doses of STZ for 5 days. Seventy-two male mice in separate groups received various doses of silymarin (20, 40, and 80 mg/kg) concomitant or after induction of diabetes for 21 days. Blood glucose and pancreatic biomarkers of inflammation and toxic stress (IL-1β, TNF-α, myeloperoxidase, lipid peroxidation, protein oxidation, thiol molecules, and total antioxidant capacity) were determined. Silymarin treatment reduced levels of inflammatory cytokines such as TNF-α and IL-1β and oxidative stress mediators like myeloperoxidase activity, lipid peroxidation, carbonyl and thiol content of pancreatic tissue in an almost dose dependent manner. No marked difference between the prevention of T1DM and the reversion of this disease by silymarin was found. Use of silymarin seems to be helpful in T1DM when used as pretreatment or treatment. Benefit of silymarin in human T1DM remains to be elucidated by clinical trials.
    Central European Journal of Biology 09/2009; 4(3):369-380. DOI:10.2478/s11535-009-0014-4 · 0.63 Impact Factor
Show more